/

Società

HA

Non verificato

HAYA Therapeutics

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMultimedialitàOncologia

4 comunicati stampa

Guarda tutti i comunicati

03/06/2025

HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics Platform

Fonte

HAYA Therapeutics

Emittente

1.00

0

13/03/2025

HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer

Fonte

HAYA Therapeutics

Emittente

1.00

0

11/09/2024

Multimedialità

Mercato del lavoro

Cardiologia

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Scienza

Medicina - Varie

HAYA Therapeutics Appoints Cardiology and Genetics Medicines Expert Jordan Shin, M.D., Ph.D. as Chief Medical Officer

Fonte

HAYA Therapeutics

Emittente

1.00

0

01/07/2024

HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award

Fonte

HAYA Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0